Etanercept biosimilar - YL Biologics

Drug Profile

Etanercept biosimilar - YL Biologics

Alternative Names: YLB-113

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lupin
  • Developer YL Biologics
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 07 Feb 2018 YL Biologics announces intention to submit MAA to PMDA for Rheumatoid arthritis
  • 07 Feb 2018 Interim efficacy, immunogenecity and adverse events data from a phase III trial in rheumatoid arthritis released by YL Biologics
  • 02 Aug 2017 YL Biologics completes a phase III trial in Rheumatoid arthritis in Bulgaria, Spain, Czech Republic, Latvia, Hungary (SC) (EudraCT2015-002809-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top